Community Diagnostic Hub positioning statement from AXREM Radiotherapy SFG


There is funding available to develop community Diagnostic hubs across NHSE. The aim to catch 75% of Cancer diagnosis at an early stage. The benefit of this is that treatment will be more successful and patients will have better outcomes, increasing survival rates for patients. Radiotherapy treatment significantly benefits 40% of cancer patients and in other developed countries over 60% of cancer patients receive Radiotherapy.

 AXREM Radiotherapy SFC wanted to highlight the potential benefit of engaging with the NHS Trusts to consider funding for Radiotherapy equipment within these CDH’s so that patients can move more swiftly from diagnosis to therapy.



AXREM’s member companies supply most of the diagnostic medical imaging and radiotherapy equipment installed in UK hospitals. They work with Consultant Radiologists, Radiographers and Practitioners, Oncologists, and a wide range of healthcare professionals in delivering healthcare to patients using our technologies.

Our members have unique knowledge, experience and insight into the workflow and challenges faced by healthcare professionals on a day-to-day basis, which enables us to develop and offer innovative solutions to improve the speed and quality of diagnostic procedures and treatments with our ultimate aim of improving patient care.

Although our members operate in a highly competitive commercial environment and in strict conformity with UK laws and regulations, certain issues such as this require focus and resolution on an industry-wide basis.

For further information about this press release please contact AXREM Director – Sally Edgington

AXREM, Rotherwick House, 3 Thomas More Street, London, E1W 1YZ